Manufacturing

Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech. 

Articles

Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost. 

Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As cell and gene therapies become more prominent, industry is seeking the expertise and capabilities of outsourcing partners to ensure success.

Sourcing Success in Cell and Gene Therapy Development

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

The need for manufacturing speed inspires contract manufacturers to explore advanced processing technologies.

More Capacity and Technology Translate to More Options

The new facility, to be operated under the newly formed CDMO, The Center for Breakthrough Medicines, will be located in King of Prussia, PA, and will increase manufacturing capacity for cell and gene therapies.

The Discovery Labs, Deerfield Management Create New CDMO and Invest $1.1 Billion in New Cell and Gene Therapy Facility

The new course is directed at analyzing the skills gap in the manufacture of cell and gene therapies as they progress toward manufacturing at scale.



CGT Catapult Partners with the University of Hertfordshire for Cell and Gene Therapy Course

The new company will work to provide the manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies through individual company products and expertise.

Bio-Techne, Fresenius Kabi, Wilson Wolf Form Joint Venture for Cell and Gene Therapy

The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer.

Astellas, Adaptimmune Form Cell Therapy Pact Worth Up to $897.5 million

GE Healthcare Life Sciences’ new facility for cell and gene processing supplies will be open in 2022. 

GE Builds Single-Use Kit Manufacturing Facility in Switzerland

The next-generation gene editing system can be applied to the development of novel cell and gene therapies.

Horizon Discovery Grants Access to Base Editing Technology

ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.


Manufacturing, Cell Therapies